PPD, Inc. (PPD) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $47.28. It has a SharesGrow Score of 45/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is PPD = $40 (-15.4% upside).
Financials: revenue is $4.7B, +16.2%/yr average growth. Net income is $154M, growing at +34.2%/yr. Net profit margin is 3.3% (thin). Gross margin is 38.4% (-10.4 pp trend).
Balance sheet: total debt is $4.5B with negative equity of -$747M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 1.12 (adequate). Debt-to-assets is 70.7%. Total assets: $6.3B.
Analyst outlook: 6 / 15 analysts rate PPD as buy (40%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 18/100 (Fail), Growth 90/100 (Pass), Past 100/100 (Pass), Health 25/100 (Fail), Moat 33/100 (Fail), Future 16/100 (Fail), Income 30/100 (Fail).
